Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985822 | 0.96 | KMT2A (0.65) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3105329 | 0.85 | KMT2A (0.69) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3001164 | 0.84 | KMT2A (0.51) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2985916 | 0.82 | KMT2A (0.71) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2989146 | 0.82 | PKM (0.50) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2985901 | 0.81 | KMT2A (0.62) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2996113 | 0.81 | KMT2A (0.65) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL5915297 | 0.81 | KMT2A (0.83) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2996937 | 0.81 | KMT2A (0.47) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL5474564 | 0.81 | KMT2A (0.64) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507536-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8263588-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2008124614-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | KMT2A 1562/4885MEN1 592/4885ALDH1A1 2873/4885 |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | KMT2A 1562/4885MEN1 592/4885ALDH1A1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.